Movement Disorders (revue)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Beyond the iron mask: Towards better recognition and treatment of depression associated with Parkinson's disease

Identifieur interne : 006568 ( Main/Merge ); précédent : 006567; suivant : 006569

Beyond the iron mask: Towards better recognition and treatment of depression associated with Parkinson's disease

Auteurs : David J. Burn [Royaume-Uni]

Source :

RBID : ISTEX:5DBBDE16B41926CCD7D766FA7F1B8832F1297D5B

English descriptors

Abstract

This review examines the frequency of depression complicating Parkinson's disease (PD), its aetiology and clinical features, and also how it may be recognised and treated. Studies investigating the frequency of depression in PD have yielded figures ranging between 2.7% and 70%. Methodological differences account for much of the disparity. The aetiology of depression in PD is complex, and probably relates to both biological and exogenous factors. Dysfunction of multiple neurotransmitter systems, including the serotonergic system, may be involved. Mood disturbances resulting from deep brain stimulation of the subthalamic nucleus may provide a fruitful area for future research, and assist our understanding of the neural networks involved in mediating depression. Several recent studies have confirmed that depression in the PD patient is a major determinant of quality of life and that this is closely related to dysfunction in other clinically important health areas. The validity for many existing scales in the screening, diagnosis, and monitoring of depression in the PD patient has not been established. The Montgomery‐Åsberg Depression Rating Scale and the Hamilton Rating Scale for Depression appear to have good diagnostic sensitivity and specificity when compared with DSM‐IV criteria. Recommendations for the optimal drug treatment of depression in PD are difficult to give, due to an inexplicable dearth of sizeable, placebo‐controlled studies. A majority of physicians would probably now opt for a selective serotonin reuptake inhibitor in the depressed PD patient. There is no good evidence that these drugs are associated with a worsening of motor features, but they should probably not be coprescribed with selegiline, because of the risk of causing a potentially serious serotonin syndrome. Several studies have suggested that depression in the PD patient is associated with a more rapid deterioration in cognitive and motor functions, perhaps as a surrogate marker for more extensive brainstem cell loss. © 2002 Movement Disorder Society

Url:
DOI: 10.1002/mds.10114

Links toward previous steps (curation, corpus...)


Links to Exploration step

ISTEX:5DBBDE16B41926CCD7D766FA7F1B8832F1297D5B

Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Beyond the iron mask: Towards better recognition and treatment of depression associated with Parkinson's disease</title>
<author>
<name sortKey="Burn, David J" sort="Burn, David J" uniqKey="Burn D" first="David J." last="Burn">David J. Burn</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:5DBBDE16B41926CCD7D766FA7F1B8832F1297D5B</idno>
<date when="2002" year="2002">2002</date>
<idno type="doi">10.1002/mds.10114</idno>
<idno type="url">https://api.istex.fr/document/5DBBDE16B41926CCD7D766FA7F1B8832F1297D5B/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000003</idno>
<idno type="wicri:Area/Istex/Curation">000003</idno>
<idno type="wicri:Area/Istex/Checkpoint">002E54</idno>
<idno type="wicri:doubleKey">0885-3185:2002:Burn D:beyond:the:iron</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:12112190</idno>
<idno type="wicri:Area/PubMed/Corpus">003A68</idno>
<idno type="wicri:Area/PubMed/Curation">003A68</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003B84</idno>
<idno type="wicri:Area/Ncbi/Merge">000783</idno>
<idno type="wicri:Area/Ncbi/Curation">000783</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000783</idno>
<idno type="wicri:doubleKey">0885-3185:2002:Burn D:beyond:the:iron</idno>
<idno type="wicri:Area/Main/Merge">006568</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main" xml:lang="en">Beyond the iron mask: Towards better recognition and treatment of depression associated with Parkinson's disease</title>
<author>
<name sortKey="Burn, David J" sort="Burn, David J" uniqKey="Burn D" first="David J." last="Burn">David J. Burn</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Consultant and Senior Lecturer in Neurology, Regional Neurosciences Centre, Newcastle General Hospital, and University of Newcastle upon Tyne, Newcastle upon Tyne</wicri:regionArea>
<wicri:noRegion>Newcastle upon Tyne</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint>
<publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="2002-05">2002-05</date>
<biblScope unit="vol">17</biblScope>
<biblScope unit="issue">3</biblScope>
<biblScope unit="page" from="445">445</biblScope>
<biblScope unit="page" to="454">454</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">5DBBDE16B41926CCD7D766FA7F1B8832F1297D5B</idno>
<idno type="DOI">10.1002/mds.10114</idno>
<idno type="ArticleID">MDS10114</idno>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Antidepressive Agents (therapeutic use)</term>
<term>Antidepressive Agents, Second-Generation (therapeutic use)</term>
<term>Antidepressive Agents, Tricyclic (therapeutic use)</term>
<term>Brain (metabolism)</term>
<term>Depressive Disorder (diagnosis)</term>
<term>Depressive Disorder (drug therapy)</term>
<term>Depressive Disorder (etiology)</term>
<term>Depressive Disorder (psychology)</term>
<term>Humans</term>
<term>Parkinson Disease (complications)</term>
<term>Parkinson Disease (metabolism)</term>
<term>Parkinson Disease (psychology)</term>
<term>Parkinson's disease</term>
<term>Psychiatric Status Rating Scales</term>
<term>Quality of Life</term>
<term>Serotonin Uptake Inhibitors (therapeutic use)</term>
<term>Treatment Outcome</term>
<term>aetiology</term>
<term>clinical features</term>
<term>depression</term>
<term>treatment</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Antidepressive Agents</term>
<term>Antidepressive Agents, Second-Generation</term>
<term>Antidepressive Agents, Tricyclic</term>
<term>Serotonin Uptake Inhibitors</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en">
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en">
<term>Depressive Disorder</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Depressive Disorder</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en">
<term>Depressive Disorder</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en">
<term>Brain</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="psychology" xml:lang="en">
<term>Depressive Disorder</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Humans</term>
<term>Psychiatric Status Rating Scales</term>
<term>Quality of Life</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">This review examines the frequency of depression complicating Parkinson's disease (PD), its aetiology and clinical features, and also how it may be recognised and treated. Studies investigating the frequency of depression in PD have yielded figures ranging between 2.7% and 70%. Methodological differences account for much of the disparity. The aetiology of depression in PD is complex, and probably relates to both biological and exogenous factors. Dysfunction of multiple neurotransmitter systems, including the serotonergic system, may be involved. Mood disturbances resulting from deep brain stimulation of the subthalamic nucleus may provide a fruitful area for future research, and assist our understanding of the neural networks involved in mediating depression. Several recent studies have confirmed that depression in the PD patient is a major determinant of quality of life and that this is closely related to dysfunction in other clinically important health areas. The validity for many existing scales in the screening, diagnosis, and monitoring of depression in the PD patient has not been established. The Montgomery‐Åsberg Depression Rating Scale and the Hamilton Rating Scale for Depression appear to have good diagnostic sensitivity and specificity when compared with DSM‐IV criteria. Recommendations for the optimal drug treatment of depression in PD are difficult to give, due to an inexplicable dearth of sizeable, placebo‐controlled studies. A majority of physicians would probably now opt for a selective serotonin reuptake inhibitor in the depressed PD patient. There is no good evidence that these drugs are associated with a worsening of motor features, but they should probably not be coprescribed with selegiline, because of the risk of causing a potentially serious serotonin syndrome. Several studies have suggested that depression in the PD patient is associated with a more rapid deterioration in cognitive and motor functions, perhaps as a surrogate marker for more extensive brainstem cell loss. © 2002 Movement Disorder Society</div>
</front>
</TEI>
<double doi="10.1002/mds.10114">
<ISTEX>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Beyond the iron mask: Towards better recognition and treatment of depression associated with Parkinson's disease</title>
<author>
<name sortKey="Burn, David J" sort="Burn, David J" uniqKey="Burn D" first="David J." last="Burn">David J. Burn</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:5DBBDE16B41926CCD7D766FA7F1B8832F1297D5B</idno>
<date when="2002" year="2002">2002</date>
<idno type="doi">10.1002/mds.10114</idno>
<idno type="url">https://api.istex.fr/document/5DBBDE16B41926CCD7D766FA7F1B8832F1297D5B/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000003</idno>
<idno type="wicri:Area/Istex/Curation">000003</idno>
<idno type="wicri:Area/Istex/Checkpoint">002E54</idno>
<idno type="wicri:doubleKey">0885-3185:2002:Burn D:beyond:the:iron</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main" xml:lang="en">Beyond the iron mask: Towards better recognition and treatment of depression associated with Parkinson's disease</title>
<author>
<name sortKey="Burn, David J" sort="Burn, David J" uniqKey="Burn D" first="David J." last="Burn">David J. Burn</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Consultant and Senior Lecturer in Neurology, Regional Neurosciences Centre, Newcastle General Hospital, and University of Newcastle upon Tyne, Newcastle upon Tyne</wicri:regionArea>
<wicri:noRegion>Newcastle upon Tyne</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint>
<publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="2002-05">2002-05</date>
<biblScope unit="vol">17</biblScope>
<biblScope unit="issue">3</biblScope>
<biblScope unit="page" from="445">445</biblScope>
<biblScope unit="page" to="454">454</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">5DBBDE16B41926CCD7D766FA7F1B8832F1297D5B</idno>
<idno type="DOI">10.1002/mds.10114</idno>
<idno type="ArticleID">MDS10114</idno>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Parkinson's disease</term>
<term>aetiology</term>
<term>clinical features</term>
<term>depression</term>
<term>treatment</term>
</keywords>
</textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">This review examines the frequency of depression complicating Parkinson's disease (PD), its aetiology and clinical features, and also how it may be recognised and treated. Studies investigating the frequency of depression in PD have yielded figures ranging between 2.7% and 70%. Methodological differences account for much of the disparity. The aetiology of depression in PD is complex, and probably relates to both biological and exogenous factors. Dysfunction of multiple neurotransmitter systems, including the serotonergic system, may be involved. Mood disturbances resulting from deep brain stimulation of the subthalamic nucleus may provide a fruitful area for future research, and assist our understanding of the neural networks involved in mediating depression. Several recent studies have confirmed that depression in the PD patient is a major determinant of quality of life and that this is closely related to dysfunction in other clinically important health areas. The validity for many existing scales in the screening, diagnosis, and monitoring of depression in the PD patient has not been established. The Montgomery‐Åsberg Depression Rating Scale and the Hamilton Rating Scale for Depression appear to have good diagnostic sensitivity and specificity when compared with DSM‐IV criteria. Recommendations for the optimal drug treatment of depression in PD are difficult to give, due to an inexplicable dearth of sizeable, placebo‐controlled studies. A majority of physicians would probably now opt for a selective serotonin reuptake inhibitor in the depressed PD patient. There is no good evidence that these drugs are associated with a worsening of motor features, but they should probably not be coprescribed with selegiline, because of the risk of causing a potentially serious serotonin syndrome. Several studies have suggested that depression in the PD patient is associated with a more rapid deterioration in cognitive and motor functions, perhaps as a surrogate marker for more extensive brainstem cell loss. © 2002 Movement Disorder Society</div>
</front>
</TEI>
</ISTEX>
<PubMed>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson's disease.</title>
<author>
<name sortKey="Burn, David J" sort="Burn, David J" uniqKey="Burn D" first="David J" last="Burn">David J. Burn</name>
<affiliation wicri:level="1">
<nlm:affiliation>Neurology, Regional Neurosciences Centre, Newcastle General Hospital, and University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom. d.j.burn@ncl.ac.uk</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Neurology, Regional Neurosciences Centre, Newcastle General Hospital, and University of Newcastle upon Tyne, Newcastle upon Tyne</wicri:regionArea>
<wicri:noRegion>Newcastle upon Tyne</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2002">2002</date>
<idno type="RBID">pubmed:12112190</idno>
<idno type="pmid">12112190</idno>
<idno type="doi">10.1002/mds.10114</idno>
<idno type="wicri:Area/PubMed/Corpus">003A68</idno>
<idno type="wicri:Area/PubMed/Curation">003A68</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003B84</idno>
<idno type="wicri:Area/Ncbi/Merge">000783</idno>
<idno type="wicri:Area/Ncbi/Curation">000783</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000783</idno>
<idno type="wicri:doubleKey">0885-3185:2002:Burn D:beyond:the:iron</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson's disease.</title>
<author>
<name sortKey="Burn, David J" sort="Burn, David J" uniqKey="Burn D" first="David J" last="Burn">David J. Burn</name>
<affiliation wicri:level="1">
<nlm:affiliation>Neurology, Regional Neurosciences Centre, Newcastle General Hospital, and University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom. d.j.burn@ncl.ac.uk</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Neurology, Regional Neurosciences Centre, Newcastle General Hospital, and University of Newcastle upon Tyne, Newcastle upon Tyne</wicri:regionArea>
<wicri:noRegion>Newcastle upon Tyne</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series>
<title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint>
<date when="2002" type="published">2002</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Antidepressive Agents (therapeutic use)</term>
<term>Antidepressive Agents, Second-Generation (therapeutic use)</term>
<term>Antidepressive Agents, Tricyclic (therapeutic use)</term>
<term>Brain (metabolism)</term>
<term>Depressive Disorder (diagnosis)</term>
<term>Depressive Disorder (drug therapy)</term>
<term>Depressive Disorder (etiology)</term>
<term>Depressive Disorder (psychology)</term>
<term>Humans</term>
<term>Parkinson Disease (complications)</term>
<term>Parkinson Disease (metabolism)</term>
<term>Parkinson Disease (psychology)</term>
<term>Psychiatric Status Rating Scales</term>
<term>Quality of Life</term>
<term>Serotonin Uptake Inhibitors (therapeutic use)</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Antidepressive Agents</term>
<term>Antidepressive Agents, Second-Generation</term>
<term>Antidepressive Agents, Tricyclic</term>
<term>Serotonin Uptake Inhibitors</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en">
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en">
<term>Depressive Disorder</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Depressive Disorder</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en">
<term>Depressive Disorder</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en">
<term>Brain</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="psychology" xml:lang="en">
<term>Depressive Disorder</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Humans</term>
<term>Psychiatric Status Rating Scales</term>
<term>Quality of Life</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">This review examines the frequency of depression complicating Parkinson's disease (PD), its aetiology and clinical features, and also how it may be recognised and treated. Studies investigating the frequency of depression in PD have yielded figures ranging between 2.7% and 70%. Methodological differences account for much of the disparity. The aetiology of depression in PD is complex, and probably relates to both biological and exogenous factors. Dysfunction of multiple neurotransmitter systems, including the serotonergic system, may be involved. Mood disturbances resulting from deep brain stimulation of the subthalamic nucleus may provide a fruitful area for future research, and assist our understanding of the neural networks involved in mediating depression. Several recent studies have confirmed that depression in the PD patient is a major determinant of quality of life and that this is closely related to dysfunction in other clinically important health areas. The validity for many existing scales in the screening, diagnosis, and monitoring of depression in the PD patient has not been established. The Montgomery-Asberg Depression Rating Scale and the Hamilton Rating Scale for Depression appear to have good diagnostic sensitivity and specificity when compared with DSM-IV criteria. Recommendations for the optimal drug treatment of depression in PD are difficult to give, due to an inexplicable dearth of sizeable, placebo-controlled studies. A majority of physicians would probably now opt for a selective serotonin reuptake inhibitor in the depressed PD patient. There is no good evidence that these drugs are associated with a worsening of motor features, but they should probably not be coprescribed with selegiline, because of the risk of causing a potentially serious serotonin syndrome. Several studies have suggested that depression in the PD patient is associated with a more rapid deterioration in cognitive and motor functions, perhaps as a surrogate marker for more extensive brainstem cell loss.</div>
</front>
</TEI>
</PubMed>
</double>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006568 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 006568 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Merge
   |type=    RBID
   |clé=     ISTEX:5DBBDE16B41926CCD7D766FA7F1B8832F1297D5B
   |texte=   Beyond the iron mask: Towards better recognition and treatment of depression associated with Parkinson's disease
}}

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024